期刊文献+

非酒精性脂肪肝患者血清脂联素、肿瘤坏死因子α水平的研究 被引量:4

Study of the level of adiponection and tumor necrosis factor α of NAFLD
下载PDF
导出
摘要 目的了解非酒精性脂肪肝(NAFLD)患者血清脂连素、肿瘤坏死因子α的水平,评价其在NAFLD发生发展过程中的作用。方法选择经B超及病史诊断为NAFLD患者132例与健康体检者157例,对空腹血糖(FBG)、空腹胰岛素(FINS)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、血清脂联素、肿瘤坏死因子α(TNFα)进行检测,计算胰岛素抵抗指数(HOMA-IR)并进行对照分析。结果与对照组相比,NAFLD观察组血清FBG、ALT、AST水平升高(P<0.05),FINS、TNFα及HOMA-IR明显升高(P<0.01)。血清脂联素水平明显下降(P<0.01)。血清脂联素水平与HOMA-IR、TNFα呈负相关(r值分别为-0.79,-0.61,P均<0.01)。结论NAFLD患者存在胰岛素抵抗,血清脂联素水平降低,肿瘤坏死因子α水平升高。 Objective To study the level of adiponectin and tumor necrosis factor aof patients of NAFLD.Methods 132 patients with NAFLD and 157 normal controls were choosed, Fastingblood sugar (FBG),fasting blood imulin (FINS),insulin resistant index(HOMA-IR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), adiponectin and tumor necrosis factor awere detected and compared with nomal conrols. Results Compared with control group, the lever of FBG, ALT, AST increased ( P 〈 0.05) ,FINS, TNTa and HOMA-IR show the obvious difference( P 〈 0.01 ), and the level of adiponectin decreased obviously( P 〈 0.01). ThelevelofadiponectinhadnegativewithHOMA-IRandTNFa(r= -0.79,P〈O.Ol,O.61,P〈O.O1).Condusion Insulin resistant were present in NAFLD, which had lower plasma adiponectin and higher TNFa.
作者 方继伟 尹林
出处 《中国实验诊断学》 2008年第10期1275-1276,共2页 Chinese Journal of Laboratory Diagnosis
关键词 非酒精性脂肪肝 脂联素 肿瘤坏死因子A nonalcoholic fatty liver diseases adiponectin tumor necrosis factor a
  • 相关文献

参考文献6

  • 1Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity[ J ]. Biochem Biophys Res Commun, 1999,257:79.
  • 2Weyer C, Funahashi T, Arita Y, et al. Hyperadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia[ J] .J Clin Endocrinol Metab,2001,86:1930.
  • 3Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1513
  • 4Day CP. Pathology of steatohepatitis [ J ]. Best Pract Res Clin Gastroenterol, 2002,16(5) :663.
  • 5Yu S, Matsusue K, Kashireddy P, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxlsome proliferatoractivated receptorγ1 ( PPARγ1 ) overexpression [ J ]. J Biol Chem, 2003, 278(1):498.
  • 6Xu A,Wang Y,Keshaw H,et al.The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice[J]. J Clin Invest,2003,112( 1 ) :91.

二级参考文献18

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献1512

同被引文献34

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部